Subcutaneous insulin: pharmacokinetic variability and glycemic variability

Area of Science:

• Endocrinology
• Pharmacology
• Metabolic Diseases

Background:

• Achieving tight glycemic control (HbA1c < 6.5-7%) in insulin-treated diabetes is challenging due to conventional insulin limitations.
• Conventional insulins exhibit slow absorption, delayed/unpredictable peak action, and significant pharmacokinetic variability, increasing hypoglycemia risk and hindering optimal glucose management.
• These drawbacks contribute to insufficient glucose control in type 1 diabetes and may delay insulin initiation in type 2 diabetes.

Purpose of the Study:

• To review the pharmacokinetic and pharmacodynamic characteristics of novel short-acting and long-acting insulin analogs.
• To discuss the intra- and inter-individual variability of these new insulin analogs compared to conventional insulins.
• To explore how improved insulin analogs can facilitate tighter glucose control and new therapeutic strategies.

Main Methods:

• Review of pharmacokinetic and pharmacodynamic data for new insulin analogs (lispro, aspart, glulisine, glargine, detemir).
• Comparative analysis of variability and reproducibility of insulin analog action versus conventional human insulins.
• Discussion of clinical implications for insulin regimens, including basal-bolus technique.

Main Results:

• New short-acting and long-acting insulin analogs demonstrate improved pharmacokinetic profiles with reduced absorption times and more predictable peak action.
• These insulin analogs exhibit significantly lesser within- and between-subject variability compared to conventional insulins.
• The enhanced predictability and reproducibility of insulin analogs facilitate tighter glucose control and support physiological insulin regimens.

Conclusions:

• Novel insulin analogs offer superior pharmacokinetic and pharmacodynamic properties, characterized by reduced variability and improved reproducibility.
• These advancements enable more effective achievement of therapeutic glycemic targets and minimize the risk of hypoglycemic events.
• Insulin analogs are pivotal in reinforcing physiological insulin regimens like basal-bolus therapy, paving the way for optimized treatment strategies in type 1 and type 2 diabetes.